Viyash Scientific Ltd is Rated Hold

Current Rating and Its Significance

The 'Hold' rating assigned to Viyash Scientific Ltd indicates a balanced outlook for investors. It suggests that while the stock may not be an immediate buy, it is not recommended for sale either. This rating reflects a moderate risk-reward profile, where investors are advised to maintain their existing positions and monitor the company’s developments closely. The rating was revised from 'Sell' to 'Hold' on 11 May 2026, following a notable improvement in the company’s overall mojo score, which increased by 17 points to 63.0.

Here’s How the Stock Looks Today

As of 06 July 2026, Viyash Scientific Ltd is classified as a smallcap company operating within the Pharmaceuticals & Biotechnology sector. The stock has demonstrated strong price momentum recently, with a one-day gain of 0.48%, a one-week increase of 9.58%, and a remarkable three-month surge of 51.20%. Over the past year, the stock has delivered a robust return of 56.94%, significantly outperforming broader market indices such as the BSE500.

Quality Assessment

The company’s quality grade is currently below average, reflecting some concerns regarding its long-term fundamental strength. The average Return on Capital Employed (ROCE) stands at a modest 5.81%, indicating limited efficiency in generating profits from its capital base. Operating profit growth over the last five years has averaged 18.70% annually, which, while positive, suggests moderate expansion compared to industry leaders. Investors should consider this cautious quality profile when evaluating the stock’s potential for sustained growth.

Valuation Perspective

Viyash Scientific Ltd is presently considered expensive based on its valuation metrics. The stock trades at a Price to Book (P/B) ratio of 4.4, which is high relative to typical benchmarks. Despite this, it is trading at a discount compared to its peers’ historical valuations, offering some relative value. The company’s Return on Equity (ROE) is 6.5%, which, combined with a Price/Earnings to Growth (PEG) ratio of 1.2, suggests that the current price reflects expectations of continued profit growth. Investors should weigh the premium valuation against the company’s growth prospects and sector dynamics.

Financial Trend and Performance

The financial trend for Viyash Scientific Ltd is outstanding, underscored by exceptional recent results. The company reported a staggering 539.5% growth in net profit in March 2026, marking nine consecutive quarters of positive earnings. Quarterly operating profit to interest coverage ratio is strong at 12.69 times, indicating robust ability to service debt. Profit Before Tax (PBT) excluding other income reached ₹109.32 crores, growing at an extraordinary rate of 629.29%, while quarterly PAT surged by 446.4% to ₹52.11 crores. These figures highlight a significant turnaround and strong operational momentum.

Technical Outlook

Technically, the stock is rated bullish, supported by consistent upward price trends and strong relative strength. Over the last six months, the stock has appreciated by 42.73%, and year-to-date gains stand at 42.01%. This positive technical momentum complements the company’s improving fundamentals and supports the 'Hold' rating, signalling that the stock may continue to perform well in the near term, though investors should remain vigilant for any shifts in market conditions.

Shareholding and Market Position

The majority shareholding is held by promoters, which often indicates stable management control and alignment with shareholder interests. The company’s consistent returns over the past three years, including outperforming the BSE500 index annually, reinforce its position as a resilient player within its sector.

What the Hold Rating Means for Investors

For investors, the 'Hold' rating on Viyash Scientific Ltd suggests maintaining current positions rather than initiating new buys or selling off shares. The rating reflects a stock that has demonstrated strong recent financial performance and technical strength but still carries valuation concerns and moderate quality metrics. Investors should monitor quarterly earnings and sector developments closely, as further improvements in quality or valuation could warrant a reassessment of the rating.

Summary of Key Metrics as of 06 July 2026

To summarise, the stock’s mojo score stands at 63.0, placing it firmly in the 'Hold' category. The company’s financials reveal:

• Net profit growth of 539.5% in the latest quarter
• Operating profit growth averaging 18.70% annually over five years
• Return on Capital Employed (ROCE) at 5.81%
• Price to Book ratio of 4.4, indicating expensive valuation
• Consistent positive quarterly results for nine consecutive quarters
• Strong technical momentum with a 56.94% return over the past year

These factors collectively justify the current 'Hold' stance, balancing the company’s operational strengths against valuation and quality considerations.

Outlook and Considerations

Looking ahead, investors should watch for sustained profit growth and improvements in capital efficiency to potentially upgrade the stock’s rating. The pharmaceutical and biotechnology sector remains competitive and subject to regulatory and innovation risks, which may impact future performance. Given the stock’s recent strong returns and bullish technicals, it remains an attractive option for investors seeking exposure to smallcap pharma companies with growth potential, albeit with a cautious approach.

Conclusion

Viyash Scientific Ltd’s current 'Hold' rating by MarketsMOJO reflects a nuanced view of the company’s prospects as of 06 July 2026. While the stock has delivered impressive returns and demonstrated outstanding financial trends recently, its below-average quality grade and expensive valuation temper enthusiasm. Investors are advised to maintain their holdings and monitor developments closely, balancing the stock’s growth potential against inherent risks.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →